Introduction
Oral and injectable semaglutide are different products with different labels, uses, and study evidence. Rybelsus is an oral type 2 diabetes product; Wegovy is an injectable chronic weight-management product.
OASIS 1 found -15.1% mean weight change with oral semaglutide 50 mg at 68 weeks, while STEP 1 found -14.9% with weekly injectable semaglutide 2.4 mg at 68 weeks, but those were separate trials, not a dose-equivalence study.
What each product is
Rybelsus is oral semaglutide with a type 2 diabetes indication and label-specific administration requirements. Wegovy is injectable semaglutide for chronic weight management. The route question starts with which labeled use matches the clinical goal, not with a milligram conversion.
We may earn a commission if you start a program through links on this page. It doesn't change prices or how we sort them. Disclosure
LIVE CATALOGCurrent telehealth prices and providers
Some provider links below are affiliate links. If you start a program through one, Telehealth Ledger may earn a commission at no extra cost to you. Commissions do not change this order.
These rows come from Telehealth Ledger's canonical catalog. A low headline price only ranks when medication is included and the continuing or prepaid basis is comparable.
| Provider | Published price | What is included |
|---|---|---|
| #1 PlexusDx | $149compounded (not FDA-approved), checked 22 October 2026 a month, continuing Visit provider Affiliate link · we may earn a commission | Semaglutide Oral · Daily oral tablets, provider-titrated; one price at every dose · medication included Month-to-month is $149, billed monthly. A 3-month plan is $129/mo ($387 up front), a 6-month plan is $109/mo ($654 up front), and a 12-month plan is $99/mo ($1,188 up front). The page calls $99 the starting price. Same price at every dose. Provider visit, medication, and shipping are included. No membership fee. Price source · checked 22 October 2026 |
| #2 Strut Health | $199compounded (not FDA-approved), checked 20 October 2026 a month, continuing Visit provider Affiliate link · we may earn a commission | Compounded Semaglutide Oral · 30-day sublingual lozenge supply · medication includedPrice source · checked 20 October 2026 |
| #3 MyDrHank | $249compounded (not FDA-approved), checked 21 October 2026 a month, continuing Visit provider Affiliate link · we may earn a commission | Oral Semaglutide · Daily oral tablet · medication includedPrice source · checked 21 October 2026 |
| #4 RxSpan MD | $249compounded (not FDA-approved), checked 22 October 2026 a month, continuing Visit provider Affiliate link · we may earn a commission | Semaglutide Oral Capsules · Oral capsules · medication included The weight-loss category calls $249 the Regular Monthly Price for Semaglutide Capsules. A separate 12-month line of $162/mo ($1,933 upfront) is not the regular monthly price. Price source · checked 22 October 2026 |
| #5 MangoRx | $299compounded (not FDA-approved), checked 19 October 2026 a month, continuing Visit provider Affiliate link · we may earn a commission | Slim · Mint-flavored oral dissolving tablet; compounded semaglutide 1–6 mg with vitamin B6 · medication included Checked 19 October 2026. The plan card says $299/month, billed monthly, cancel anytime. The hero also says Starting at $299/mo. No other dollar price is on the page. The card lists the consultation, tablets, and shipping as included. Price source · checked 19 October 2026 |
Showing the 5 lowest comparable published prices from 7 eligible providers. The complete comparison includes every current catalog row.
- Curex: $49 first month starting price; exact renewal quote after intakecompounded (not FDA-approved)Last checked 7 Oct 2026Medication included as published
- MEDGm: $319/mo effective • $957 prepaid every 3 monthscompounded (not FDA-approved)Medication included as published
- MEDGm: $289/mo effective • $1,734 prepaid every 6 monthscompounded (not FDA-approved)Medication included as published
| Provider | Published price | What is included |
|---|---|---|
| #1 Sesame Care | $349, checked 20 October 2026 a month after 2 months at $199/month; plus $99/month care Visit provider Affiliate link · we may earn a commission | Wegovy® pen · Weekly injection · medication included Medication: $199/month for the first two months for eligible new self-pay patients at 0.25 or 0.5 mg, then $349/month. Offer ends December 31, 2026. Care is $99/month separately; $59/month requires an annual care commitment. Price source · checked 20 October 2026 |
| #2 RxSpan MD | $1,349, checked 22 October 2026 a month, continuing Visit provider Affiliate link · we may earn a commission | Wegovy® · Weekly branded injection · medication included The weight-loss category card prints $1,349 (For the first month). It does not print a separate later monthly price. Price source · checked 22 October 2026 |
| #3 GobyMeds | $1,695, checked 22 October 2026 a month, continuing Visit provider | Wegovy® · Weekly injection · medication includedPrice source · checked 22 October 2026 |
- DrHouse: $129 self-pay visit or insurance copayMedication or membership billed separately
- Measured: Product page $99/mo membership; homepage from $49; medication separate ($199–$349/mo cash range)Last checked 7 Oct 2026Medication or membership billed separately
- MEDGm: $99 membership + medication cost (medication total not published)Medication or membership billed separately
| Provider | Published price | What is included |
|---|---|---|
| #1 Gala Health | $1,299, checked 21 October 2026 a month, continuing Visit provider Affiliate link · we may earn a commission | Ozempic® · Weekly injection · medication included The Ozempic product page says From $1,299/month, cash price. It says insurance may reduce the cost. That page shows no other dollar price. Price source · checked 21 October 2026 |
| #2 RxSpan MD | $1,299, checked 22 October 2026 a month, continuing Visit provider Affiliate link · we may earn a commission | Ozempic® · Weekly branded injection · medication included The weight-loss category card prints $1,299 (For the first month). It does not print a separate later monthly price. Price source · checked 22 October 2026 |
- DrHouse: $129 self-pay visit or insurance copayMedication or membership billed separately
- MEDGm: $171 membership + medication cost (medication total not published)Medication or membership billed separately
- Shed Rx: Starting at $599/mo. Hero $149 is CMS template bleed.Last checked 14 Sept 2026Medication included as published
Eligibility, prescribed quantity, state availability, pharmacy fulfillment, shipping, supplies, and follow-up can change the final cost. Unknown fields remain unknown.
What the oral and injectable trials found
OASIS 1 studied oral semaglutide 50 mg in adults with overweight or obesity and reported -15.1% mean weight change at 68 weeks, compared with -2.4% with placebo. STEP 1 reported -14.9% with weekly injectable semaglutide 2.4 mg and -2.4% with placebo at 68 weeks. Trial populations and regimens were separate.
| Decision point | What the cited evidence can answer |
|---|---|
| Exact product | Confirm the approved indication, route, and formulation |
| Outcome evidence | Keep direct trials separate from indirect study comparisons |
| Practical fit | Review safety history, other medicines, follow-up, and access |
Which route may fit the real decision
An oral option brings daily label-specific administration requirements and possible interaction considerations. An injectable option has its own administration and supply considerations. The clinician can weigh the approved use, other medicines, tolerance, practical routine, and evidence base without treating oral and injectable milligrams as equivalent.
What OASIS 1 studied
OASIS 1 tested oral semaglutide 50 mg in adults with overweight or obesity. It is not a direct comparison with STEP 1.
| Question | Evidence-based check |
|---|---|
| Exact product | Confirm the approved product, formulation, and labeled indication |
| Evidence | Keep direct trials separate from indirect comparisons |
| Access | Verify provider terms and price basis independently |
Shared safety does not erase differences
Both routes require attention to contraindications, GI symptoms, interactions, pregnancy plans, and procedures.
Ask a route-specific question
Ask how the approved indication, evidence, administration burden, other medicines, and access apply to the individual.
What the cited sources establish
The comparison starts with different evidence tracks: Rybelsus is an oral semaglutide diabetes product, Wegovy is an injectable weight-management product, OASIS 1 studied oral semaglutide 50 mg in a defined obesity population, and STEP 1 studied weekly injectable semaglutide 2.4 mg. These are not a dose-for-dose head-to-head trial.
The numerical similarity between OASIS 1 and STEP 1 headline results does not create a conversion rule. The studies used different oral and injectable regimens and were designed separately. The practical comparison is therefore about the product's approved use, route-specific instructions, daily versus weekly routine, other medicines, and whether the proposed use has a matching evidence base, rather than which number looks easier to compare.
Route affects more than convenience. Oral semaglutide carries tablet-specific administration requirements, while injectable semaglutide has injection-product instructions and a different labeled use in this comparison. The reader should also ask whether other oral medicines, schedule consistency, GI tolerance, or a need for weight-management rather than diabetes evidence changes the balance. Those are concrete tradeoffs that the separate trial headlines cannot resolve by themselves.
Questions that change the next review
A route discussion should cover the approved indication, each product's administration instructions, other oral medicines, adherence realities, safety history, and which study evidence matches the proposed use. A clinician can then explain whether a route change is clinically sensible without treating milligrams as interchangeable.
Route selection becomes concrete when the clinician identifies the approved use, the daily or weekly routine, relevant oral medicines, and the evidence that supports that particular product rather than an adjacent formulation.
Product details that still need verification
This page does not translate oral milligrams into injection amounts or imply that oral trial findings automatically replace an approved injectable regimen. Shared semaglutide exposure does not erase different labels, formulations, and use conditions. A pharmacy offer also needs its own formulation verification.
Do not convert oral and injectable milligrams. Rybelsus and Wegovy have different labeled uses. OASIS 1 and STEP 1 are not a direct head-to-head study. A route switch needs product-specific clinical review. Oral and injectable semaglutide should not be compared dose-for-dose. Current labels describe different products, indications, formulations, and administration requirements, and OASIS 1 is trial evidence rather than an automatic substitute for an approved injectable regimen. The next step is a clinician-led review of the exact product and your situation.
Use the current product label and prompt clinical care for urgent symptoms or medication changes.
Common questions
- What does the evidence show about Oral vs Injectable Semaglutide: Approved Uses, Evidence, and Questions for Your Clinician?
- Oral and injectable semaglutide should not be compared dose-for-dose. Current labels describe different products, indications, formulations, and administration requirements, and OASIS 1 is trial evidence rather than an automatic substitute for an approved injectable regimen.
- Can I use this as dosing or switching advice?
- No. This page excludes personalized dosing, conversions, and self-directed treatment changes.
- What should I check before acting?
- Check the current product label, the exact formulation, and the plan with the prescribing clinician.
- Why are labels named so often?
- Products can share an ingredient while having different approved uses, formulations, warnings, and evidence.
Use evidence to improve the next clinical conversation
Oral and injectable semaglutide should not be compared dose-for-dose. Current labels describe different products, indications, formulations, and administration requirements, and OASIS 1 is trial evidence rather than an automatic substitute for an approved injectable regimen. The next step is a clinician-led review of the exact product and your situation.
Already on a oral semaglutide plan? See which of 7 providers charge less than yours
Starting from scratch? How to get compounded oral semaglutide online
Sources
- FDA primary materialFDA · Accessed 28 August 2026
Primary evidence supporting oral vs injectable semaglutide.
- FDA primary materialFDA · Accessed 28 August 2026
Primary evidence supporting oral vs injectable semaglutide.
- Clinical study recordPubMed · Accessed 28 August 2026
Primary evidence supporting oral vs injectable semaglutide.
- Clinical study recordPubMed · Accessed 28 August 2026
Primary evidence supporting oral vs injectable semaglutide.
- Clinical guidelineAmerican Diabetes Association · Accessed 28 August 2026
Primary evidence supporting oral vs injectable semaglutide.
Refresh triggers
- A new FDA label or Medication Guide
- A new major clinical-trial publication
- An ADA or AGA guideline update
- A material change to the verified provider registry